To ask the Secretary of State for Health and Social Care, what discussions he has had with NHS England on ensuring adequate numbers of NHS employees are available to administer Tofersen.
I have had no such discussions. The National Institute for Health and Care Excellence (NICE) has selected tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations as a topic for guidance development through its Highly Specialised ...
Tofersen